CSIMarket
 


Oxford Immunotec Global Plc  (OXFD)
Other Ticker:  
 

Oxford Immunotec Global Plc's Leverage Ratio

OXFD's quarterly Leverage Ratio and Total Liabilities, Equity growth


Due to net new borrowings of 8.63%, Leverage Ratio fell to 0.1, below the Oxford Immunotec Global Plc's average Leverage Ratio.

Within In Vitro & In Vivo Diagnostic Substances industry in the third quarter 2020, 39 other companies have achieved lower Leverage Ratio than Oxford Immunotec Global Plc in the III Quarter 2020. While Leverage Ratio total ranking has deteriorated compared to the second quarter 2020 from 176 to 243 .

Explain Leverage Ratio?
Who are OXFD Customers?
What are OXFD´s Total Liabilities?


OXFD Leverage Ratio (Sep 30 2020)
III. Quarter
(Jun 30 2020)
II. Quarter
(Mar 31 2020)
I. Quarter
(Dec 31 2019)
IV. Quarter
(Sep 30 2019)
III. Quarter
Y / Y Equity Change -11.03 % -13.27 % -8.41 % -0.15 % 198.71 %
Y / Y Total Liabilities Change -19.82 % -26.95 % -16.14 % 53.92 % -50.62 %
Leverage Ratio MRQ 0.1 0.09 0.11 0.1 0.11
OXFD's Total Ranking # 243 # 176 # 158 # 122 # 187
Seq. Equity Change 1.25 % -4.6 % -7.34 % -0.59 % -1.29 %
Seq. Total Liabilities Change 8.63 % -15.95 % -2.26 % -10.15 % -1.04 %



Leverage Ratio third quarter 2020 Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 40
Healthcare Sector # 123
Overall Market # 243


Leverage Ratio Statistics
High Average Low
0.97 0.28 0.07
(Jun 30 2017)   (Dec 31 2018)




Financial Statements
Oxford Immunotec Global Plc's Equity $ 191 Millions Visit OXFD's Balance sheet
Oxford Immunotec Global Plc's Total Liabilities $ 19 Millions Visit OXFD's Balance sheet
Source of OXFD's Sales Visit OXFD's Sales by Geography


Cumulative Oxford Immunotec Global Plc's Leverage Ratio

OXFD's Leverage Ratio for the trailling 12 Months

OXFD Leverage Ratio

(Sep 30 2020)
III. Quarter
(Jun 30 2020)
II. Quarter
(Mar 31 2020)
I. Quarter
(Dec 31 2019)
IV. Quarter
(Sep 30 2019)
III. Quarter
Y / Y Equity TTM Growth -11.03 % -13.27 % -8.41 % -0.15 % 198.71 %
Y / Y Total Liabilities TTM Growth -19.82 % -26.95 % -16.14 % 53.92 % -50.62 %
Leverage Ratio TTM 0.1 0.1 0.11 0.11 0.1
Total Ranking TTM # 6 # 95 # 108 # 202 # 180
Seq. Equity TTM Growth 1.25 % -4.6 % -7.34 % -0.59 % -1.29 %
Seq. Total Liabilities TTM Growth 8.63 % -15.95 % -2.26 % -10.15 % -1.04 %


On the trailing twelve months basis Despite of the net new borrowings of 8.63% during the twelve months period ending in III Quarter 2020 Oxford Immunotec Global Plc has managed to unchanged Leverage Ratio in the III Quarter 2020 to 0.1, a new company low.
Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the In Vitro & In Vivo Diagnostic Substances industry OXFD recorded the lowest Leverage Ratio. While Leverage Ratio total ranking has improved so far to 6, from total ranking in previous 12 month period at 95.

Explain Leverage Ratio?
Who are OXFD Customers?
What are OXFD´s Total Liabilities?

TTM Leverage Ratio Company Ranking
Within: No.
Within the In Vitro & In Vivo Diagnostic Substances Industry # 0
Healthcare Sector # 0
Within the Market # 6


trailing twelve months Leverage Ratio Statistics
High Average Low
0.78 0.32 0.1
(Dec 31 2017)   (Sep 30 2020)




Companies with similar Leverage Ratio in the quarter ending Sep 30 2020, within In Vitro & In Vivo Diagnostic Substances Industry Leverage RatioSep 30 2020 MRQ Total LiabilitiesSep 30 2020 MRQ Equity
Biomerica Inc   0.26 $ 3.312  Millions$ 12.581  Millions
Mymd Pharmaceuticals Inc   0.12 $ 2.515  Millions$ 21.169  Millions
Celldex Therapeutics inc   0.11 $ 25.795  Millions$ 229.975  Millions
Oxford Immunotec Global Plc  0.10 $ 19.241  Millions$ 191.259  Millions
Neogen Corporation  0.09 $ 70.046  Millions$ 751.546  Millions
Achieve Life Sciences Inc   0.08 $ 1.942  Millions$ 25.675  Millions
Arca Biopharma Inc   0.03 $ 1.527  Millions$ 50.455  Millions

Date modified: -0001-11-30T00:00:00+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com